**Problem:** Myelodysplastic Syndrome (MDS) is a blood disorder that often requires recurrent platelets (PLT) transfusion (2-3 x week) in elderly patients as a palliative treatment.

**Solution:** An injectable device “Mini Marrow” containing a biomaterial scaffold, supportive cells and blood stem cells with the capacity to sustain a long-term production of human platelets PLTs (~3 months).

---

1. **Who are your clients?**

58.5 million people suffer from MDS worldwide. We aim to treat 30% of patients with this orphan disease, that is 17.55 million people, with Mini Marrow.

2. **How do you make money?**

Right now every PLT transfusion has a cost of 500-600 CHF/unit (~71,500 CHF/Year/ Patient). Mini Marrow is estimated to have a cost of 1,089 CHF/unit (4,357 CHF/Year/ Patient).

3. **What gives you credibility?**

- We have already initiated our R&D process obtaining promising results with Mini Marrow in mice.
- We have launched a patent to protect our USP.

---

“We aim to substitute the current regime of 2-3 times platelet transfusions per week for a unique Mini Marrow injection every ~3 months”

---

**TEAM MEMBERS**

1. Josefine Tratwal, PhD (UNIL)
2. Marc Serulla, MSc (UNIL)
3. Hadrien Loriot, BSc (EHL)

---

**Next steps**

1. What are you going to do in next 6 months

We will continue our R&D process to obtain an MVP “Mini Marrow” ready for first clinical trials, while also applying for funding.

2. HR needed after the training

We will need more technical staff to further develop “Mini Marrow” in the R&D process to obtain a MVP and attract investors.

3. What kind of support that you are looking for: Further training / coaching / funding

Coaching and funding